Posts
7 years ago
Donna Karan, Charla Lawhorn, InStyle and Kelly Ripa invite you to Super Saturday 10-Saturday July 28th, 2007
Donna Karan, Charla Lawhorn, InStyle and Kelly Ripa invite you to
" Super Saturday 10!!! July 28th, Watermill, NY
" The Hottest Happenings in the Hamptons!!!!
Exclusive preview shopping (Noon to 6:00 p.m.) @ $600.00Adult tickets (1:00 p.m. to 6:00 p.m.) @ $400.00 Kids tickets @ $100.00 each (ages 5-16; kids under 5 are admitted free)
Tickets for Super Saturday 10 will be available online beginning June 11, 2007.
" Super Saturday" ~ Coined " The Rolls Royce of Shopping events" !!
Super Saturday 10!!
July 28th, 2007 " Super Saturday"
Nova's Ark Project, Watermill, NY
Time: 1-6 PM
http://www.ocrf.org/site/c.kwK0JbNTJtF/b.810571/k.90EC/Super_Saturday__Ticket_Info.htm
" Super Saturday 10!!! July 28th, Watermill, NY
" The Hottest Happenings in the Hamptons!!!!
Exclusive preview shopping (Noon to 6:00 p.m.) @ $600.00Adult tickets (1:00 p.m. to 6:00 p.m.) @ $400.00 Kids tickets @ $100.00 each (ages 5-16; kids under 5 are admitted free)
Tickets for Super Saturday 10 will be available online beginning June 11, 2007.
" Super Saturday" ~ Coined " The Rolls Royce of Shopping events" !!
Super Saturday 10!!
July 28th, 2007 " Super Saturday"
Nova's Ark Project, Watermill, NY
Time: 1-6 PM
http://www.ocrf.org/site/c.kwK0JbNTJtF/b.810571/k.90EC/Super_Saturday__Ticket_Info.htm
Share~ A Second Helping of Life "Tasting Event"
A Second Helping of Life
A Tasting Event to Benefit SHARE
Featuring New York's Top Women Chefs
Pier 60 at Chelsea Piers
Monday, September 17, 2007
7:00-9:30 PM
Ticket prices: $300 & $500
For more information, to buy tickets, to reserve a table of 10, or to inquire about corporate sponsorship, please contactAlice Yaker at ayaker@sharecancersupport.org or (212) 937-5570.
$1 million offered for cancer 'ideas'
$1 million offered for cancer 'ideas'
Investors hope to spark innovative research
Friday, May 25, 2007
BY CAROL ANN CAMPBELL Star-Ledger Staff
A group of New York investors will award $1 million a year to the person with the "best idea" in cancer research -- and the idea will be shared worldwide.
The "Gotham Prize" will encourage novel thinking and counter the competitive interests that can hinder progress, its creators said yesterday.
The first $1 million will be awarded next February. An advisory board that includes scientists from Harvard University, the Johns Hopkins University and the Cancer Institute of New Jersey will select the winners, who can use the money any way they choose.
"It's going to encourage people to talk to each other and collaborate," said Joseph R. Bertino, interim director of the cancer institute. "Well get out-of-the-box thinking."
Organizers say the award is unique in the world of medical research. They will pre-qualify members, who will post their ideas and concepts on a Web site, www.gothamprize.org. Other researchers and scientists viewing the site can build on the ideas, or perhaps assist or collaborate on individual projects.
"We're trying to encourage people to share their ideas. Even if four or five great ideas come out of this it will be worth it," said Gary Curhan, a medical researcher and physician at Harvard Medical School. He created the prize with hedge fund managers Joel Greenblatt and Robert Goldstein of the private investment firm Gotham Capital in New York.
One aim is for the Web site to help foundations and companies discover ideas that need funding -- and for scientists to find potential sources of money for their ideas.
Curhan said many good ideas do not get funded because researchers do not have enough preliminary data to attract government funding or because the ideas go against the grain.
Greenblatt said he and Goldstein, his partner, found similar ways to share ideas useful in the business world and thought the concept would work in medical research.
"Even people who don't win but post their ideas may get some funding or they may get collaborators to help them," Greenblatt said. The ideas can involve cancer prevention, causes, diagnosis or treatment.
Additional funding of the prize also came from Ephi Gildor of Axiom Investment Advisors and the Ira Sohn Conference Foundation, which was named after a 29-year-old Wall Street trader who died of cancer. The foundation also awards an annual $250,000 prize in pediatric oncology.
An inspiration of the prize was Hope Goldstein, Goldstein's mother, who died from ovarian cancer.
"We thought this was a good way to honor her," said Greenblatt.
Investors hope to spark innovative research
Friday, May 25, 2007
BY CAROL ANN CAMPBELL Star-Ledger Staff
A group of New York investors will award $1 million a year to the person with the "best idea" in cancer research -- and the idea will be shared worldwide.
The "Gotham Prize" will encourage novel thinking and counter the competitive interests that can hinder progress, its creators said yesterday.
The first $1 million will be awarded next February. An advisory board that includes scientists from Harvard University, the Johns Hopkins University and the Cancer Institute of New Jersey will select the winners, who can use the money any way they choose.
"It's going to encourage people to talk to each other and collaborate," said Joseph R. Bertino, interim director of the cancer institute. "Well get out-of-the-box thinking."
Organizers say the award is unique in the world of medical research. They will pre-qualify members, who will post their ideas and concepts on a Web site, www.gothamprize.org. Other researchers and scientists viewing the site can build on the ideas, or perhaps assist or collaborate on individual projects.
"We're trying to encourage people to share their ideas. Even if four or five great ideas come out of this it will be worth it," said Gary Curhan, a medical researcher and physician at Harvard Medical School. He created the prize with hedge fund managers Joel Greenblatt and Robert Goldstein of the private investment firm Gotham Capital in New York.
One aim is for the Web site to help foundations and companies discover ideas that need funding -- and for scientists to find potential sources of money for their ideas.
Curhan said many good ideas do not get funded because researchers do not have enough preliminary data to attract government funding or because the ideas go against the grain.
Greenblatt said he and Goldstein, his partner, found similar ways to share ideas useful in the business world and thought the concept would work in medical research.
"Even people who don't win but post their ideas may get some funding or they may get collaborators to help them," Greenblatt said. The ideas can involve cancer prevention, causes, diagnosis or treatment.
Additional funding of the prize also came from Ephi Gildor of Axiom Investment Advisors and the Ira Sohn Conference Foundation, which was named after a 29-year-old Wall Street trader who died of cancer. The foundation also awards an annual $250,000 prize in pediatric oncology.
An inspiration of the prize was Hope Goldstein, Goldstein's mother, who died from ovarian cancer.
"We thought this was a good way to honor her," said Greenblatt.
Ultrasound screening may catch ovarian cancer early
NEW YORK (Reuters Health) - A new study suggests that ovarian cancer screening with a technique called transvaginal ultrasonography (TVS) may catch ovarian cancer early, at a more curable stage.
Cancer & The Enviroment
Health reporter Gina Kolata discusses links between cancer and the environment with toxicologist and cancer survivor Michael Gallo. (Producer: Craig Duff)
Blocking a Path to Cancer
Scientists have discovered that cells have a built-in cancer fighting mechanism. (Produced by: Emily B. Hager)
Ultrasound screening may catch ovarian cancer early
Ultrasound screening may catch ovarian cancer early
Mon May 28, 2007 12:33PM EDT
NEW YORK (Reuters Health) - A new study suggests that ovarian cancer screening with a technique called transvaginal ultrasonography (TVS) may catch ovarian cancer early, at a more curable stage.
TVS involves using an ultrasound probe placed in the vagina to direct sound waves through the vaginal wall towards the ovaries to detect abnormalities. The new study shows that TVS screening is able to detect ovarian cancers at an earlier stage, perhaps increasing their chances of survival.
The early diagnosis of ovarian cancer is difficult and the disease is often not detected until it has reached an advanced stage. Compared with other gynecologic cancers, ovarian cancer carries a very poor prognosis.
Dr. John R. van Nagell, from the University of Kentucky in Lexington, and colleagues assessed the value of annual TVS screening for ovarian cancer in 25,327 women who were seen between 1987 and 2005.
To be eligible for the study, the women had to be at least 50 years old with no cancer-related symptoms or at least 25 years old with a family history of ovarian cancer.
Overall, 364 women (1.4 percent) had a persistent ovarian tumor on TVS, the authors report in the journal Cancer. Malignant cases included 35 primary invasive ovarian cancers, 9 ovarian tumors of low malignant potential, and 7 "metastatic" cancers that had already spread beyond the ovaries. Most of the contained or "non-metastatic" ovarian tumors were early stage I tumors.
During an average follow-up of about 5 years, 38 women were alive and well, 4 had died of their cancer, and 2 had died from other causes.
The 2-year survival rate in annually TVS screened women approached 90 percent and the 5-year survival rate in screened women was a little over 77 percent.
TVS screening was highly sensitive and specific in detecting ovarian cancer. However, "false-negative" results were obtained in nine women, including three who died of their disease, the investigators note.
Summing up, the researchers say early detection of ovarian cancer could potentially improve treatment efficacy and reduce deaths. "The protective effect of annual sonographic screening on ovarian cancer mortality observed in the current trial should only increase as more specific biomarkers are added to TVS in screening algorithms," they conclude.
Mon May 28, 2007 12:33PM EDT
NEW YORK (Reuters Health) - A new study suggests that ovarian cancer screening with a technique called transvaginal ultrasonography (TVS) may catch ovarian cancer early, at a more curable stage.
TVS involves using an ultrasound probe placed in the vagina to direct sound waves through the vaginal wall towards the ovaries to detect abnormalities. The new study shows that TVS screening is able to detect ovarian cancers at an earlier stage, perhaps increasing their chances of survival.
The early diagnosis of ovarian cancer is difficult and the disease is often not detected until it has reached an advanced stage. Compared with other gynecologic cancers, ovarian cancer carries a very poor prognosis.
Dr. John R. van Nagell, from the University of Kentucky in Lexington, and colleagues assessed the value of annual TVS screening for ovarian cancer in 25,327 women who were seen between 1987 and 2005.
To be eligible for the study, the women had to be at least 50 years old with no cancer-related symptoms or at least 25 years old with a family history of ovarian cancer.
Overall, 364 women (1.4 percent) had a persistent ovarian tumor on TVS, the authors report in the journal Cancer. Malignant cases included 35 primary invasive ovarian cancers, 9 ovarian tumors of low malignant potential, and 7 "metastatic" cancers that had already spread beyond the ovaries. Most of the contained or "non-metastatic" ovarian tumors were early stage I tumors.
During an average follow-up of about 5 years, 38 women were alive and well, 4 had died of their cancer, and 2 had died from other causes.
The 2-year survival rate in annually TVS screened women approached 90 percent and the 5-year survival rate in screened women was a little over 77 percent.
TVS screening was highly sensitive and specific in detecting ovarian cancer. However, "false-negative" results were obtained in nine women, including three who died of their disease, the investigators note.
Summing up, the researchers say early detection of ovarian cancer could potentially improve treatment efficacy and reduce deaths. "The protective effect of annual sonographic screening on ovarian cancer mortality observed in the current trial should only increase as more specific biomarkers are added to TVS in screening algorithms," they conclude.
Differences in Ovarian Cancer Cells and Normal Ovarian Cells
Differences in Ovarian Cancer Cells and Normal Ovarian Cells
Comparison of normal ovarian cells with advanced ovarian cancer cells demonstrated genetic differences (study at the Medical University of Vienna, Clinic for Internal Medicine). In normal ovarian cells two genes are always activated, N33 and EFA6R. In some cases, these genes are almost completely inactivated in ovarian cancer cells. It appears as if these genes lose their ability to function before the onset of clinical symptoms, and are therefore good candidates for early identification of the disease.
Comparison of normal ovarian cells with advanced ovarian cancer cells demonstrated genetic differences (study at the Medical University of Vienna, Clinic for Internal Medicine). In normal ovarian cells two genes are always activated, N33 and EFA6R. In some cases, these genes are almost completely inactivated in ovarian cancer cells. It appears as if these genes lose their ability to function before the onset of clinical symptoms, and are therefore good candidates for early identification of the disease.
Freezing Ovarian Tissue for Later Transplantation May Restore Fertility
Freezing Ovarian Tissue for Later Transplantation May Restore Fertility
Researchers in New York reported an intriguing finding last week that may offer hope for women who become infertile as a result of cancer treatments like chemotherapy or radiotherapy. In a brief paper published in the March 13 issue of The Lancet, a team from the NewYork-Presbyterian Hospital/Weill Cornell Medical Center reported on a case in which they cryopreserved ovarian tissue from a 30-year-old woman with breast cancer before she underwent chemotherapy. Six years later, after the woman had undergone successful treatment for cancer, the tissue was thawed and transplanted beneath the skin of her abdomen. The patient's ovarian function returned after three months.
Over the next eight months, the team was able to retrieve eight viable oocytes for use in in-vitro fertilization with her husband's sperm. From this, one four-cell embryo was produced and transferred to the patient's uterus. She did not, however, become pregnant. In a news release, the lead investigator, Dr. Kutluk Oktay, said the research "represents a potentially significant reproductive advancement in two respects: first, women can preserve their fertility by freezing their ovarian tissue, and second, pregnancy may be possible even after the tissue remains frozen for a long time."
In an editorial that accompanied the study, Prof. Johan Smitz from the Centre for Reproductive Medicine, University Hospital of the Vrije Universiteit Brussels, Belgium, offered words of caution. Because of many unknowns related to cryopreservation and screening tissue for transplant, he wrote, this option "should still be presented as experimental to patients."
Researchers in New York reported an intriguing finding last week that may offer hope for women who become infertile as a result of cancer treatments like chemotherapy or radiotherapy. In a brief paper published in the March 13 issue of The Lancet, a team from the NewYork-Presbyterian Hospital/Weill Cornell Medical Center reported on a case in which they cryopreserved ovarian tissue from a 30-year-old woman with breast cancer before she underwent chemotherapy. Six years later, after the woman had undergone successful treatment for cancer, the tissue was thawed and transplanted beneath the skin of her abdomen. The patient's ovarian function returned after three months.
Over the next eight months, the team was able to retrieve eight viable oocytes for use in in-vitro fertilization with her husband's sperm. From this, one four-cell embryo was produced and transferred to the patient's uterus. She did not, however, become pregnant. In a news release, the lead investigator, Dr. Kutluk Oktay, said the research "represents a potentially significant reproductive advancement in two respects: first, women can preserve their fertility by freezing their ovarian tissue, and second, pregnancy may be possible even after the tissue remains frozen for a long time."
In an editorial that accompanied the study, Prof. Johan Smitz from the Centre for Reproductive Medicine, University Hospital of the Vrije Universiteit Brussels, Belgium, offered words of caution. Because of many unknowns related to cryopreservation and screening tissue for transplant, he wrote, this option "should still be presented as experimental to patients."
Ovarian Cancer Prevention and Early Detection Study-ongoing
Ovarian Cancer Prevention and Early Detection Study
Name of the TrialProspective Screening Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening in Participants at Increased Genetic Risk of Ovarian Cancer (GOG-0199). See the protocol summary at http://cancer.gov/clinicaltrials/GOG-0199.
Principal InvestigatorDr. Mark H. Greene of NCI's Clinical Genetics Branch, DCEG
Why Is This Trial Important?
Ovarian cancer is the fifth leading cause of cancer death among U.S. women. The lifetime risk of ovarian cancer in the general population is about 1.4 percent by age 70. But, women with mutations in the BRCA1 or BRCA2 genes face cumulative risks of 16-40 percent. For these women, preventive removal of the ovaries and fallopian tubes does lower the risk of ovarian and breast cancer, but the magnitude of these reductions is still uncertain.
Neither the impact of preventive surgery on quality of life, nor the consequences of premature menopause, have been carefully studied in women at high risk. At present, there is no proven screening strategy shown to decrease mortality due to ovarian cancer.
This national trial, conducted with the Gynecologic Oncology Group and the Cancer Genetics Network, will more precisely quantify the extent of cancer risk reduction after preventive surgery, assess both quality of life and incidence of non-cancer diseases related to premature menopause, and evaluate a novel approach to ovarian cancer screening based on quantitative assessment of changes in CA-125 over time.
"About 30 percent of women with ovarian cancer survive longer than five years," said Dr. Greene. "But, if diagnosed and treated before the cancer spreads beyond the ovaries, 90-95 percent of patients live longer than five years. Developing effective prevention and early detection methods is crucial in fighting this disease, particularly for women who are at much greater risk."
Who Can Join This Trial?
The trial seeks to enroll 1,800 women aged 30 or over who are at increased risk of ovarian cancer, either because they or a close relative have a BRCA1 or BRCA2 mutation or because of a strong family history of ovarian and/or breast cancer. See the full list of eligibility criteria at http://cancer.gov/clinicaltrials/GOG-0199.
Where Is This Trial Taking Place?
Multiple study sites are enrolling patients in this trial. See the list of sites at http://cancer.gov/clinicaltrials/GOG-0199.
Who to ContactCall the Gynecologic Oncology Group at 1-800-225-3053 to learn which sites have opened this trial or view the study Web site at http://ovariancancer.GOG199.cancer.gov/.
Name of the TrialProspective Screening Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening in Participants at Increased Genetic Risk of Ovarian Cancer (GOG-0199). See the protocol summary at http://cancer.gov/clinicaltrials/GOG-0199.
Principal InvestigatorDr. Mark H. Greene of NCI's Clinical Genetics Branch, DCEG
Why Is This Trial Important?
Ovarian cancer is the fifth leading cause of cancer death among U.S. women. The lifetime risk of ovarian cancer in the general population is about 1.4 percent by age 70. But, women with mutations in the BRCA1 or BRCA2 genes face cumulative risks of 16-40 percent. For these women, preventive removal of the ovaries and fallopian tubes does lower the risk of ovarian and breast cancer, but the magnitude of these reductions is still uncertain.
Neither the impact of preventive surgery on quality of life, nor the consequences of premature menopause, have been carefully studied in women at high risk. At present, there is no proven screening strategy shown to decrease mortality due to ovarian cancer.
This national trial, conducted with the Gynecologic Oncology Group and the Cancer Genetics Network, will more precisely quantify the extent of cancer risk reduction after preventive surgery, assess both quality of life and incidence of non-cancer diseases related to premature menopause, and evaluate a novel approach to ovarian cancer screening based on quantitative assessment of changes in CA-125 over time.
"About 30 percent of women with ovarian cancer survive longer than five years," said Dr. Greene. "But, if diagnosed and treated before the cancer spreads beyond the ovaries, 90-95 percent of patients live longer than five years. Developing effective prevention and early detection methods is crucial in fighting this disease, particularly for women who are at much greater risk."
Who Can Join This Trial?
The trial seeks to enroll 1,800 women aged 30 or over who are at increased risk of ovarian cancer, either because they or a close relative have a BRCA1 or BRCA2 mutation or because of a strong family history of ovarian and/or breast cancer. See the full list of eligibility criteria at http://cancer.gov/clinicaltrials/GOG-0199.
Where Is This Trial Taking Place?
Multiple study sites are enrolling patients in this trial. See the list of sites at http://cancer.gov/clinicaltrials/GOG-0199.
Who to ContactCall the Gynecologic Oncology Group at 1-800-225-3053 to learn which sites have opened this trial or view the study Web site at http://ovariancancer.GOG199.cancer.gov/.
Living With Cancer---Discovery Channel-Sunday, May 6, at 8 p.m
Dear Khrissy:
I wanted to take a minute to let all of you know that on Sunday May 6, Discovery Channel will air a special three-hour broadcast of Koppel on Discovery dedicated to the discussion of living with cancer.
The special, moderated by Ted Koppel, has two segments. In the first segment you will see taped conversations between Koppel, Lance Armstrong and Leroy Sievers. In the conversation between Armstrong and Koppel, Armstrong speaks candidly and even credits cancer with contributing to the full, rich life that he leads today.
Looking back on his 1996 diagnosis, Armstrong recalls the pain of watching his mother react to the heartbreaking news that her only child had a 50/50 chance of surviving the disease. He describes the grueling nature of the chemotherapy he received, and reflects on the competition that arose between him and his cancer.
In his conversation with Sievers, Koppel’s longtime executive producer and friend, they talk about what it's like to face the prospect of dying, as well as the highs and lows that come with living with cancer.
In the second segment Elizabeth Edwards will join Koppel, Armstrong and Sievers for a live town hall meeting. During this segment the panel will interact with an audience comprised entirely of people living with cancer, their loved ones and the professionals who care for them.
This special highlights the urgent need we have to change the way we fight cancer. It is time for Americans to demand that our nation's leaders make fighting cancer a national priority. If you have not signed the LIVESTRONG Army petition, please sign it today and unite in a call for change. Or, please forward the petition to 5 friends inviting them to join our efforts.
So make sure you tune in Sunday night (Discovery Channel, 8 PM ET) to see the premiere of Living with Cancer. It will truly be an emotional and memorable night.
LIVESTRONG,
Doug Ulman
President of the Lance Armstrong Foundation
www.livestrong.org
I wanted to take a minute to let all of you know that on Sunday May 6, Discovery Channel will air a special three-hour broadcast of Koppel on Discovery dedicated to the discussion of living with cancer.
The special, moderated by Ted Koppel, has two segments. In the first segment you will see taped conversations between Koppel, Lance Armstrong and Leroy Sievers. In the conversation between Armstrong and Koppel, Armstrong speaks candidly and even credits cancer with contributing to the full, rich life that he leads today.
Looking back on his 1996 diagnosis, Armstrong recalls the pain of watching his mother react to the heartbreaking news that her only child had a 50/50 chance of surviving the disease. He describes the grueling nature of the chemotherapy he received, and reflects on the competition that arose between him and his cancer.
In his conversation with Sievers, Koppel’s longtime executive producer and friend, they talk about what it's like to face the prospect of dying, as well as the highs and lows that come with living with cancer.
In the second segment Elizabeth Edwards will join Koppel, Armstrong and Sievers for a live town hall meeting. During this segment the panel will interact with an audience comprised entirely of people living with cancer, their loved ones and the professionals who care for them.
This special highlights the urgent need we have to change the way we fight cancer. It is time for Americans to demand that our nation's leaders make fighting cancer a national priority. If you have not signed the LIVESTRONG Army petition, please sign it today and unite in a call for change. Or, please forward the petition to 5 friends inviting them to join our efforts.
So make sure you tune in Sunday night (Discovery Channel, 8 PM ET) to see the premiere of Living with Cancer. It will truly be an emotional and memorable night.
LIVESTRONG,
Doug Ulman
President of the Lance Armstrong Foundation
www.livestrong.org
Ovarian Cancer Awareness Postage Stamp Petition
PLEASE SIGN Petition to HELP STAMP OUT
OVARIAN CANCER!!!
Awareness & early detection is the only way to lick Ovarian Cancer.
To date there is not an early detection test for Ovarian Cancer.
Please forward the petition to all your friends!
Please sign the " LIVESTRONG ARMY PETITION"
A Small Step for Cancer.
Dear Friends,
Recently, President Bush signed a bill to reauthorize the National Breast and Cervical Cancer Early Detection program, an initiative that provides free breast and cervical cancer screenings to uninsured and low-income women.
The reauthorization is a critical first step in saving lives, but it alone does not solve the problem. That’s because under current funding levels, the program covers only one in five eligible women. You read that right: Five women need the care. One will receive it.
That’s not good enough. There is a serious gap between what we know works—and what we do to fight cancer. The question is, are we willing to do what it takes to fix this problem?
You can help close this gap by signing the LIVESTRONG Army petition today and uniting to make cancer a national priority. Please take a minute to sign the petition. My name is the first on it.
We know, and the Institute of Medicine confirms, that low-income women are three times more likely to die from breast cancer. Why? This same group is less likely to get screened and more likely to be diagnosed with late-stage cancer. In other words, we could prevent these deaths. In fact, one-third of the 560,000 cancer deaths that occur in the United States each year could be prevented by applying what we already know about prevention, screening and early detection.
We know what to do. We aren’t doing it.
We must close the gap between what we know works – early detection and access to care- and what we do – which, for the past several years, has been to watch Congress and the Administration under-fund life-saving cancer programs.
Please join me as part of the LIVESTRONG Army by signing the petition below and uniting in a call for change. It will only take a minute and it will make a big difference.
It is time for Americans to demand that our nation’s leaders make fighting cancer a national priority. Literally hundreds of thousands of lives depend on it.
Dear Friends,
Recently, President Bush signed a bill to reauthorize the National Breast and Cervical Cancer Early Detection program, an initiative that provides free breast and cervical cancer screenings to uninsured and low-income women.
The reauthorization is a critical first step in saving lives, but it alone does not solve the problem. That’s because under current funding levels, the program covers only one in five eligible women. You read that right: Five women need the care. One will receive it.
That’s not good enough. There is a serious gap between what we know works—and what we do to fight cancer. The question is, are we willing to do what it takes to fix this problem?
You can help close this gap by signing the LIVESTRONG Army petition today and uniting to make cancer a national priority. Please take a minute to sign the petition. My name is the first on it.
We know, and the Institute of Medicine confirms, that low-income women are three times more likely to die from breast cancer. Why? This same group is less likely to get screened and more likely to be diagnosed with late-stage cancer. In other words, we could prevent these deaths. In fact, one-third of the 560,000 cancer deaths that occur in the United States each year could be prevented by applying what we already know about prevention, screening and early detection.
We know what to do. We aren’t doing it.
We must close the gap between what we know works – early detection and access to care- and what we do – which, for the past several years, has been to watch Congress and the Administration under-fund life-saving cancer programs.
Please join me as part of the LIVESTRONG Army by signing the petition below and uniting in a call for change. It will only take a minute and it will make a big difference.
It is time for Americans to demand that our nation’s leaders make fighting cancer a national priority. Literally hundreds of thousands of lives depend on it.
GCF 12th Ovarian Cancer Survivors Course-Saturday July 12th, 2007
GCF is pleased to announce its 12th Ovarian Cancer Survivors Course! This course will be held Saturday, July 21, 2007, 9:00 a.m. – 4:00 p.m. in Philadelphia, PA at the Philadelphia Marriott Downtown Hotel. Complete course details are available on the GCF Web site (www.gcf.org).
GCF is pleased to offer this FREE Course for all ovarian cancer survivors, friends, family members and others who are interested in hearing from the leading U.S. experts in ovarian cancer research. These experts will share new information about ovarian cancer, and time for questions and answers, as well as networking with other survivors, will be provided.
Online registration for the course is now available.
Plans are currently underway for a course in New York in September. Be sure to bookmark the GCF Web site for more information!
Please contact the GCF with any questions!
Travel Assistance
American Airlines is the Official Airlines of the GCF. GCF has arranged a special discount with American Airlines for all attendees to the Ovarian Cancer Survivors Courses this year. Make your air reservations with American Airlines using authorization code A0377AM, and you will receive a discount on the lowest applicable published airfare. Purchase your ticket online and pay no fees for booking. You will be able to receive AAdvantage Miles on all flights. Please note that this may not be used in conjunction with other discounted fares or coupons.
GCF is pleased to offer this FREE Course for all ovarian cancer survivors, friends, family members and others who are interested in hearing from the leading U.S. experts in ovarian cancer research. These experts will share new information about ovarian cancer, and time for questions and answers, as well as networking with other survivors, will be provided.
Online registration for the course is now available.
Plans are currently underway for a course in New York in September. Be sure to bookmark the GCF Web site for more information!
Please contact the GCF with any questions!
Travel Assistance
American Airlines is the Official Airlines of the GCF. GCF has arranged a special discount with American Airlines for all attendees to the Ovarian Cancer Survivors Courses this year. Make your air reservations with American Airlines using authorization code A0377AM, and you will receive a discount on the lowest applicable published airfare. Purchase your ticket online and pay no fees for booking. You will be able to receive AAdvantage Miles on all flights. Please note that this may not be used in conjunction with other discounted fares or coupons.
Subscribe to:
Posts (Atom)
Upcoming Long Island Event
DOO-WOP CONCERT FOR OVARIAN CANCER
